The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Effect of carotuximab (ENV105)-mediated CD105 blockade on osimertinib sensitivity in EGFR-mutant non-small cell lung cancer persister cells.
 
Neil Bhowmick
Leadership - Enviro Therapeutics Inc.; Kairos Pharma
Stock and Other Ownership Interests - Fibrobiologics; Kairos Pharma
Consulting or Advisory Role - Fibrobiologics; Kairos Pharma
Patents, Royalties, Other Intellectual Property - Patents on Carotuximab
 
Sandrine Billet
No Relationships to Disclose
 
Barliz Waissengrin
No Relationships to Disclose
 
Kamya Sankar
Research Funding - Black Diamond Therapeutics (Inst); Genentech/Roche (Inst); Harpoon therapeutics (Inst); Lilly (Inst); Merck (Inst)
 
Edwin Posadas
Consulting or Advisory Role - Bayer
Speakers' Bureau - Bayer
Research Funding - EnviroTherapetuics, Inc (Inst); PFizer (Inst)
Patents, Royalties, Other Intellectual Property - Patent on NanoVelcro Assay for CTCs in prostate cancer
Expert Testimony - Shook, Hardy & Bacon L.L.P.
 
Sungyong You
No Relationships to Disclose
 
Jean Lopategui
No Relationships to Disclose
 
Karen Reckamp
Consulting or Advisory Role - AstraZeneca; Daiichi Sankyo/Lilly; Genentech; GlaxoSmithKline; Janssen Oncology; Merus; Novartis; Novocare; Pfizer
Research Funding - Blueprint Medicines; Daiichi Sankyo/Astra Zeneca (Inst); Elevation Oncology (Inst); Genentech/Roche (Inst); Janssen Oncology (Inst)
 
Manish Thiruvalluvan
No Relationships to Disclose